Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge

[Image: see text] Currently approved pharmacotherapies for opioid use disorders (OUDs) and overdose reversal agents are insufficient to slow the spread of OUDs due to the proliferation of fentanyl. This is evident in the 31% rise in drug overdose deaths from 2019 to 2022, with rates increasing from...

Descripción completa

Detalles Bibliográficos
Autores principales: Powers, Noah, Massena, Casey, Crouse, Bethany, Smith, Mira, Hicks, Linda, Evans, Jay T., Miller, Shannon, Pravetoni, Marco, Burkhart, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587865/
https://www.ncbi.nlm.nih.gov/pubmed/37758302
http://dx.doi.org/10.1021/acs.bioconjchem.3c00347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587865/
https://www.ncbi.nlm.nih.gov/pubmed/37758302
http://dx.doi.org/10.1021/acs.bioconjchem.3c00347

Ejemplares similares